Autologous Anti-FLT3 CAR-T Cells HG-CT-1

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of autologous T-lymphocytes genetically modified with a chimeric antigen receptor (CAR) specific for the tumor-associated antigen FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-FLT3 CAR-T cells HG-CT-1 target and bind to tumor cells expressing FLT3, which results in the cytotoxic T-lymphocyte (CTL)-mediated cell killing of FLT3-expressing tumor cells. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B-lineage neoplasms and in acute myeloid leukemias (AMLs).

**Synonyms:** - Autologous Anti-FLT3 CAR T Cells HG-CT-1 - Autologous Anti-FLT3 CAR T-cells HG-CT-1 - HEMO-CAR-T - HG-CT 1 - HG-CT-1 - HG-CT1